1487347-86-3Relevant academic research and scientific papers
METHOD FOR PRODUCING AMINO ACID DERIVATIVES
-
, (2022/01/04)
The present invention aims to provide a method for producing a (2S,5R)-5-(protected oxyamino)-piperidine-2-carboxylic acid derivative at a low cost that can be performed under mild reaction conditions not requiring a facility at an extremely low temperature, is safer, can control the quality of the desired product with ease, and shows good workability in the site of production. A method for producing a compound represented by the formula (2): wherein PG1 is an amino-protecting group, PG2 is an amino-protecting group, PG3 is a hydroxyl-protecting group, LG is a leaving group, and R is a hydrocarbon group having 1-8 carbon atoms and optionally having substituent(s), including a step of reacting a compound represented by the formula (1): wherein each symbol is as defined above, with a hydroxylamine derivative represented by the formula PG2NHOPG3 wherein each symbol is as defined above, in the presence of a base in a solvent.
METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
-
Paragraph 1238; 1241-1242, (2021/01/22)
This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
RAD51 Inhibitors
-
Paragraph 0541-0542, (2019/03/30)
This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
Synthetic method of avibactam intermediate (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate
-
, (2019/12/29)
The invention discloses a synthetic method of an avibactam intermediate (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate. N-protective group-L-pyroglutamate (SM) is taken as an initial raw material, and the (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate is obtained through six steps of reactions including trimethyl sulfoxide iodide recarburization ring opening, halogenation under the action of acid, high-selectivity reduction, lactone ring formation under the catalysis of acid, piperidine ring closing under the action of alkali and hydrolysis. The synthetic method is mild in reaction conditions, simple and convenient to operate, easy in impurity control and stable in yield. The used reagents are low in price, the cost is effectively reduced, and the method is environment-friendly and suitable for industrial production.
Stereodivergent synthesis of 5-aminopipecolic acids and application in the preparation of a cyclic RGD peptidomimetic as a nanomolar αvβ3 integrin ligand
Sernissi, Lorenzo,Ricci, Luciano,Scarpi, Dina,Bianchini, Francesca,Arosio, Daniela,Contini, Alessandro,Occhiato, Ernesto G.
, p. 3402 - 3414 (2018/05/23)
A stereodivergent strategy was devised to obtain enantiopure cis and trans 5-aminopipecolic acids (5-APAs) in suitably protected forms to be employed in peptide synthesis as conformationally constrained α- and δ-amino acids. The cis isomer was used as a δ-amino acid to construct a cyclic RGD-containing peptidomimetic, the ability of which to compete with biotinylated vitronectin for binding with the isolated αVβ3 integrin was measured (IC50 = 4.2 ± 0.9 nM). A complete 1H NMR and computational conformational analysis was performed to elucidate the reasons for the high affinity of this cyclic peptidomimetic in comparison with cilengitide.
HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 43, (2016/06/28)
The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Studies of Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N2--L-prolyl>-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds
Hagiwara, Daijiro,Miyake, Hiroshi,Igari, Norihiro,Karino, Masako,Maeda, Yasue,et al.
, p. 2090 - 2099 (2007/10/02)
As an extension of our studies on discovering a novel substance P (SP) antagonist, we modified the previously reported dipeptide, N2-2-(1H-indol-3-ylcarbonyl)-L-lysyl>-N-methyl-N-(phenylmethyl)-L-phenylalaninamide (2b).The lysine part in 2b was first optimized to a (2S,4R)-hydroxyproline derivative (3h), which is 2-fold more potent than 2b in SP binding assay using guinea pig lung membranes.Next we modified the 1H-indol-3-ylcarbonyl part in 3h.Introduction of a methyl group at the indole nitrogen enhanced the oral activity, while retaining the binding activity.Finally, we modified the phenylalanine part to culminate in the most potent compound 7k (FK888), which is a potent SP antagonist with NK1 selectivity as well as oral activity.
